ReviewFrontiers in oncology2019
Ovarian Cancer Targeted Theranostics.
Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Diabetes mellitus and the risk of ovarian cancer: a systematic review and meta-analysis of cohort and case-control studies.BMJ open · 2020Pooled it
- Nanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms.Cancers · 2025Review
- Three-Dimensional Bioprinting and Infertility-Related Female Reproductive System Diseases: A Review of Current and Future Applications.Tissue engineering and regenerative medicine · 2025Review
- Olaparib increases chemosensitivity by upregulating miR-125a-3p in ovarian cancer cells.Discover oncology · 2025Article
- Suppression of KLF5 targets RREB1 to restrain the proliferation of ovarian cancer cells through ERK/MAPK signaling pathway.3 Biotech · 2025Article
- A positive feedback loop of SRSF9/USP22/ZEB1 promotes the progression of ovarian cancer.Cancer biology & therapy · 2024Article
- Comparison ofAbdominal radiology (New York) · 2024Article
- Imaging tumor and ascites-associated macrophages in a mouse model of metastatic ovarian cancer.EJNMMI research · 2024Article
- Review
- Optimization of cobalt ferrite magnetic nanoparticle as a theranostic agent: MRI and hyperthermia.Magma (New York, N.Y.) · 2023Article
- Aggregation-induced emission photosensitizer-based photodynamic therapy in cancer: from chemical to clinical.Journal of nanobiotechnology · 2022Review
- Two novel prognostic models for ovarian cancer respectively based on ferroptosis and necroptosis.BMC cancer · 2022Article
- Effects of Autophagy-Related Genes on the Prognosis and Immune Microenvironment of Ovarian Cancer.BioMed research international · 2022Article
- The Role of Keratin17 in Human Tumours.Frontiers in cell and developmental biology · 2022Review
- Review
- Long non-coding RNA miR155HG silencing restrains ovarian cancer progression by targeting the microRNA-155-5p/tyrosinase-related protein 1 axis.Experimental and therapeutic medicine · 2021Article
- Epigenetic Silencing of miR-33b Promotes Peritoneal Metastases of Ovarian Cancer by Modulating the TAK1/FASN/CPT1A/NF-κB Axis.Cancers · 2021Article
- Article
- Article
- A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin.PloS one · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is a leading cause of death from gynecological malignancies. Although the prognosis is quite favorable if detected at an early stage, the vast majority of cases are diagnosed at an advanced stage, when 5-year survival rates are only 30-40%. Most recurrent ovarian tumors are resistant to traditional therapies underscoring the need for new therapeutic options. Theranostic agents, that combine diagnostic and therapeutic capabilities, are being explored to better detect, diagnose and treat ovarian cancer. To minimize morbidity, improve survival rates, and eventually cure patients, new strategies are needed for early detection and for delivering specifically anticancer therapies to tumor sites. In this review we will discuss various molecular imaging modalities and targets that can be used for imaging, therapeutic and theranostic agent development for improved diagnosis and treatment of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.